More than 1 million percutaneous coronary intervention
|
|
- Ethel Lawson
- 6 years ago
- Views:
Transcription
1 n report n Percutaneous Coronary Intervention: Assessing Coronary Vascular Risk Associated With Bare-Metal and Drug-Eluting Stents Sarah A. Spinler, PharmD, FCCP, BCPS (AQ Cardiology) Abstract Percutaneous coronary intervention (PCI) with stenting is increasingly being utilized for acute coronary syndromes (ACS), and the debate over the safety and efficacy of drug-eluting stents (DESs) versus bare-metal stents (BMSs) has intensified. The difficulty in consistently assessing stent safety is because of the widespread off-label use in patients with clinical features and coronary anatomy inconsistent with the approved use in stable patients with relatively noncomplex coronary stenosis, short-term follow-up of only 1 year in pivotal clinical trials that leads to approval, and inconsistency in the nature and duration of adjunctive antiplatelet therapy. Of concern are the high recurrence rates after the first episode of stent thrombosis, as demonstrated by the Dutch Stent Thrombosis Study. However, more recent analyses using better statistical models favor DESs versus BMSs, both for survival and repeat revascularizations. Recommendations from updated guidelines from the American College of Cardiology/American Heart Association/ Society for Cardiovascular Angiography and Interventions are summarized for oral antiplatelet therapy with DESs and BMSs in the management of ACS. For patients undergoing elective PCI, dual antiplatelet therapy with aspirin and clopidogrel is recommended for at least 4 weeks for a BMS and 12 months for a DES, with aspirin continued indefinitely. For patients with non ST-segment elevation ACS or ST-segment elevation myocardial infarction, dual antiplatelet therapy is recommended for at least 12 months. In summary, more recent data suggest that the benefits outweigh the risks of DESs compared with BMSs, and that the rate of DES placement will continue to rise. It is important that clinicians be aware of the indications for dual antiplatelet therapy and the appropriate durations of dual antiplatelet therapy in patients undergoing PCI. (Am J Manag Care. 2009;15:S42-S47) More than 1 million percutaneous coronary intervention (PCI) procedures are performed in the United States each year. Patients with significant lesions (>50%) in 1 or more coronary arteries are suitable for PCI and fall into 4 major categories 1 : 1) Elective PCI: asymptomatic ischemia or Canadian Cardiovascular Society class I or II angina (mild); 2) Urgent PCI: class III angina but no acute coronary syndromes (ACS) (symptoms limit physical activity); 3) Emergent or primary PCI for ST-segment elevation myocardial infarction (STEMI): acute thrombus obstructing a coronary artery; and 4) Non ST-segment elevation ACS with acute thrombus occluding or partially occluding coronary artery. May be urgent or emergent depending on symptoms and electrocardiogram findings or diagnosis of myocardial infarction (MI). 1 Originally, PCI was performed without stenting via balloon angioplasty in 1977 that reduced stenosis and relieved ischemic symptoms as well as decreased the frequency of major adverse cardiac events such as reinfarction and the need for urgent target vessel revascularization. 2 However, it was associated with elastic recoil and acute occlusion (leading to MI) as well as neointimal hyperplasia (leading to restenosis and rehospitalization). Introduced in 1994, and accounting for more than 70% of PCI by the late 1990s, bare-metal stents (BMSs) reduced the risk of acute closure, thrombosis, and restenosis. 3 Drug-eluting stents (DESs), containing antiproliferative agents, were introduced in 2003 and further reduced the rates of restenosis and early thrombosis to less than 1%. 3 Restenosis and Late Stent Thrombosis It is believed that the most prominent complication of BMSs placement is restenosis, Managed whereas that Care of DESs & is late thrombosis. However, Healthcare several contradictory Communications, reports have been published, LLC both in support of and against these observations. The difficulty in consistently assessing stent safety is because of the widespread off-label use in patients with clinical features and coronary anatomy inconsistent with the approved use in stable patients with relatively noncomplex S42 n n March 2009
2 Assessing Coronary Vascular Risk Associated With Bare-Metal and Drug-Eluting Stents coronary stenosis, short-term follow-up of only 1 year in pivotal clinical trials that leads to approval, and inconsistency in the nature and duration of adjunctive antiplatelet therapy. 4 Late stent thrombosis can occur months or even years after DES implantation and may result in catastrophic events with life-threatening complications. In addition, the high recurrence rates after the first episode of stent thrombosis are of major concern. 5 The Dutch Stent Thrombosis Study of recurrent stent thrombosis was a multicenter observational study of 431 patients who have experienced an initial thrombotic event after stent implantation. 5 Approximately 75% of the patients had ACS, and 60% received BMSs and 35% received DESs. The patients enrolled in this study had definite stent thrombosis, which was characterized as follows: acute stent thrombosis (<24 hours; 32%), subacute thrombosis, (1-30 days; 41%), late (30 days-1 year; 13%) or very late stent thrombosis (>1 year; 13%). 5 A high recurrence rate of 18.8% after the first episode of stent thrombosis was observed during a median follow-up of 27 months, contributing to all-cause mortality of 15.4%. The study showed that although a thrombotic event is not necessarily fatal, the population is at high risk for recurrent stent thrombosis and a high mortality rate, regardless of the type of stent used. Therapeutic Benefits and Risks Associated With BMSs and DESs The concerns regarding the safety and efficacy of DESs versus BMSs have intensified and are at the center of much recent debate. 6 Several recent studies have attempted to evaluate the relative therapeutic benefits and risks associated with BMSs and DESs. The propensity for off-label use and the inconsistency in adjunctive antiplatelet therapy have made the evaluation of relative risks and benefits more difficult, especially considering the uncommon but potentially serious complication of stent thrombosis. 7 Early analyses favored BMSs versus DESs, but more recent data and better statistical analyses increasingly favor DESs. 8 A recent analysis of 14 clinical trials comparing sirolimus-eluting stents (SESs) with BMSs (4958 patients and mean follow-up interval, months) concluded that the survival and risk of stent thrombosis were similar (risk of death: hazard ratio [HR], 1.03; 95% confidence interval [CI], ; stent thrombosis: HR, 1.09; 95% CI, ). 9 A more recent study of 7217 patients treated for acute MI found that the 2-year risk-adjusted mortality and repeat revascularization rates were significantly lower in DES-treated patients compared with those treated with BMSs, for both STEMI and non ST-segment elevation myocardial infarction (NSTEMI) (STEMI: mortality, 8.5% DESs vs 11.6% BMSs, P =.008; repeat revascularization, 10.2% DESs vs 13.9% BMSs, P =.003; NSTEMI: mortality, 12.8% DESs vs 15.6% BMSs, P =.04; repeat revascularization, 9.8% DESs vs 15.2% BMSs, P <.001). 10 Repeat revascularization is an important end point from a managed care perspective. In an observational study with 2-year follow-up, Malenka et al compared the outcomes of 38,917 Medicare patients undergoing nonemergent coronary stenting from October 2002 to March 2003 (BMS era) with 28,086 similar patients from September through December 2003 (DES era; 61.5% DESs and 38.5% BMSs). 11 Rates of repeat revascularization were significantly lower in the DES era versus the BMS era (PCI, 17.1% vs 20.0%, P <.001; coronary artery bypass graft [CABG], 2.7% vs 4.2%, P <.01), whereas the adjusted risk of 2-year mortality or STEMI was similar (HR, 0.96; 95% CI, ). The concern regarding off-label versus on-label stenting, for both DESs and BMSs, was addressed by a 2-year outcomes study of 1285 consecutive patients with the routine use of DESs and a comparable group of 1164 consecutive patients treated with BMSs. 12 In general, off-label use was associated with a higher incidence of nonfatal MI or death versus on-label use of DESs and BMSs (Figure). For either off-label or on-label use, DESs showed favorable end points compared with BMSs at 2 years with HRs for DESs versus BMSs for nonfatal MI or death (off-label: HR, 0.78, 95% CI, ; on-label: HR, 0.47, 95% CI, ), all-cause mortality (off-label: HR, 0.72, 95% CI, ; on-label: HR, 0.42, 95% CI, ), and target vessel revascularization (off-label: HR, 0.67, 95% CI, ; on-label: HR, 0.43, 95% CI, ). 12 Interestingly, no stent thrombosis was found in the on-label use of either BMSs or DESs, whereas the incidence of stent thrombosis was similar in the off-label use of both BMSs and VOL. 15, No. 2 n The American Journal of Managed Care n S43
3 Report DESs. Conversely, late stent thrombosis occurred only in off-label DES use, not in off-label BMS use. Note that there are limitations to observational studies that are nonrandomized with respect to potential confounding patient factors which may affect the risk of recurrent clinical events. In another study that analyzed data from 6551 patients in the National Heart, Lung, and Blood Institute Dynamic Registry, off-label use occurred in 54.7% of patients with BMSs and in 48.7% of patients with DESs. 13 At 1-year follow-up, significantly lower rates of death or MI were found for off-label use of DESs compared with off-label use of BMSs (7.5% vs 11.6%; P <.001), but no significant difference was found when comparing the standard use of DESs with BMSs. However, DESs were found to be superior to BMSs in lowering the rates of repeat revascularization for both standard use as well as offlabel use (standard use: 7.7% vs 13.4%, P <.001; offlabel: 12.7% vs 17.5%, P <.001). 13 It may be noted that in this study, patients in the DES group had a significantly higher prevalence of diabetes, hypertension, renal disease, and previous PCI (all P <.001). 13 Although DES studies are frequently grouped together for comparing outcomes with BMSs, considerable differences are observed in DESs containing different agents. A comparison of early (0-30 days) and late (<30 days) stent thrombosis rates between SESs and paclitaxel-eluting stents (PESs) documented a 2.9% cumulative incidence of angiographically proven stent thrombosis that occurred at 3 years, with late stent thrombosis occurring steadily during the 3-year period. 14 Similar incidence of early stent thrombosis was observed for SESs and PESs, whereas late stent thrombosis occurred more frequently in the PES group compared with the SES group (1.8% and 1.4%, respectively; P =.031). 14 Not surprisingly, ACS and diabetes at presentation were also independent predictors of stent thrombosis. Guidelines and Recommendations for Improving Coronary Vascular Outcomes Class I recommendations for PCI provided by the American College of Cardiology (ACC)/American Heart Association (AHA)/Society for Cardiovascular Angiography and Interventions favor DESs as an alternative to BMSs in patients with a favorable effectiveness/safety profile (Table). 15 However, prior confirmation of the ability to comply with the recommended duration of dual antiplatelet therapy (aspirin n Figure. Off-Label Versus On-Label Stenting: Kaplan-Meier Plots of Cumulative Events Up to 2 Years Nonfatal MI or Death No. at Risk Cummulative Incidence, % Off-label use vs On-label use HR: 2.53 ( ) On-label BMS On-label DES Log-rank P value < Time, days Off-label BMS Off-label DES Off-label DES Off-label BMS On-label DES On-label BMS Off-label DES vs Off-label BMS HR: 0.78 ( ) On-label DES vs On-label BMS HR: 0.47 ( ) BMS indicates bare-metal stent; DES, drug-eluting stent; HR, hazard ratio; MI, myocardial infarction. Reprinted with permission from Applegate RJ, et al. J Am Coll Cardiol. 2008;51(6): S44 n n March 2009
4 Assessing Coronary Vascular Risk Associated With Bare-Metal and Drug-Eluting Stents n Table. Key Guideline Recommendations for Improving Coronary Vascular Outcomes Post PCI (A) ACC/AHA/SCAI Updated PCI Guidelines: DES and BMS 15 Class I Recommendations A DES should be considered as an alternative to a BMS in patients for whom clinical trials indicate a favorable effectiveness/safety profile Before implanting a DES, the cardiologist should discuss with the patient the need for and duration of dual antiplatelet therapy and confirm the patient s ability to comply with the recommended therapy for DESs In patients undergoing preparation for PCI who are likely to require invasive or surgical procedures for which dual antiplatelet therapy must be interrupted during the next 12 months, consideration should be given to the use of a BMS or the performance of balloon angioplasty with provisional stent implantation Class IIb Recommendations A DES may be considered for clinical and anatomic settings in which the effectiveness/safety profile appears favorable but has not been fully confirmed by clinical trials (B) ACC/AHA/SCAI Updated PCI Guidelines: Oral Antiplatelet Therapy for Elective PCI 15 Class I Recommendations: Aspirin Patients already taking daily long-term aspirin should take mg before PCI Patients not already taking daily aspirin should be given mg of aspirin at least 2 hours and preferably 24 hours before PCI After PCI, in patients without allergy or increased risk of bleeding, aspirin mg daily should be given for at least: 1 month after BMS implantation 3 months after sirolimus-eluting stent implantation 6 months after paclitaxel-eluting stent implantation Subsequently, the recommended aspirin dose is 75 a -162 mg daily indefinitely Class I Recommendations: Clopidogrel A loading dose of clopidogrel, generally 600 mg, should be administered before or when PCI is performed In patients undergoing PCI within hours of receiving fibrinolytic therapy, a clopidogrel oral loading dose of 300 mg may be considered For all post-pci stented patients receiving a DES, clopidogrel 75 mg daily should be given for at least 12 months if the patient is not at high risk of bleeding For patients receiving a BMS, clopidogrel should be given for a minimum of 1 month and ideally up to 12 months (unless patient is at increased risk of bleeding, then it should be given for a minimum of 2 weeks) Class IIa Recommendations: Clopidogrel and Aspirin If clopidogrel is given at the time of procedure, supplementation with Gp IIb/IIIa receptor antagonists can be beneficial For patients with an absolute contraindication to aspirin, it is reasonable to give a 300- to 600-mg loading dose of clopidogrel, administered at least 6 hours before PCI, and/or Gp IIb/IIIa antagonists at the time of PCI In patients with increased risk of bleeding, a lower dose of mg of aspirin is reasonable during the initial period after stent implantation Class IIb Recommendations: Clopidogrel and Aspirin Continuation of clopidogrel therapy beyond 1 year may be considered in patients undergoing DES placement (C) ACC/AHA Updated ACS Guidelines: Aspirin and Clopidogrel 16,17 STEMI Management Class I Recommendations Aspirin mg immediately and continued indefinitely Dose reduced to 75 a -162 mg daily for long-term secondary prevention Clopidogrel 75 mg daily should be added to aspirin in patients with STEMI regardless of the reperfusion strategy Continue clopidogrel for at least 14 days If PCI performed, clopidogrel continued for BMS: minimum of 1 month and ideally up to 1 year DES: at least 1 year In patients not at high risk of bleeding Discontinue clopidogrel for 5-7 days before elective CABG surgery UA/NSTEMI Management Class I Recommendations Aspirin mg immediately and continued indefinitely Dose reduced to 75 a -162 mg daily for chronic secondary prevention Clopidogrel loading dose of mg (option of 900 mg) Daily dose 75 mg once daily continued for at least 1 month and ideally 1 year If PCI performed, clopidogrel continued for: BMS: minimum of 1 month and ideally up to 1 year DES: at least 1 year In patients not at high risk of bleeding Discontinue clopidogrel for 5-7 days before elective CABG surgery Class IIa Recommendations In patients aged <75 years who receive a fibrinolytic or no reperfusion therapy, it is reasonable to consider a 300-mg loading dose of clopidogrel Long-term clopidogrel therapy for 1 year can be considered for patients with STEMI regardless of reperfusion strategy ACC indicates American College of Cardiology; ACS, acute coronary syndrome; AHA, American Heart Association; BMS, bare-metal stent; CABG, coronary artery bypass graft; DES, drug-eluting stent; Gp, glycoprotein; NSTEMI, non ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; SCAI, Society for Cardiovascular Angiography and Interventions; STEMI, ST-segment elevation myocardial infarction; UA, unstable angina. a Available dose in the United States is 81 mg. VOL. 15, No. 2 n The American Journal of Managed Care n S45
5 Report and clopidogrel) is critical for DESs, otherwise BMSs should be considered. Patients should continue their daily aspirin regimen before PCI, but patients who do not take aspirin daily should receive an initial dose of 325 mg. Post PCI, aspirin doses of 325 mg daily are recommended for a short period of time (1-6 months, depending on stent type) in patients without the risk of allergy or bleeding, followed by lower maintenance doses indefinitely (Table). For clopidogrel, a higher loading dose of 600 mg is a new recommendation, and 75 mg daily should be given for at least 1 month and ideally up to 1 year post PCI for patients not at high risk of bleeding. 15 The ACC/AHA recommendations for dual antiplatelet therapy in the management of unstable angina/nstemi are similar to those mentioned above, with a caveat that clopidogrel should be discontinued 5 to 7 days before elective CABG surgery, and dual antiplatelet therapy is indicated, regardless of PCI, ideally for 12 months. 16 For STEMI, clopidogrel 75 mg should be added to the aspirin regimen regardless of the reperfusion strategy, and clopidogrel should be continued for at least 2 weeks. 17 For STEMI, once PCI is performed, recommendations on the duration of dual antiplatelet therapy are mandated based on stent type, according to the PCI guidelines. Understanding the Risks and Benefits of Prolonged Antiplatelet Therapy Current guideline recommendations are based on clinical trial durations with an extension of clopidogrel therapy to at least 12 months in patients with DESs. Some cardiologists may elect to continue clopidogrel therapy beyond 1 year in patients with DESs to prevent late stent thrombosis in patients at low risk of bleeding. Some clinical and angiographic predictors of DES thrombosis include advanced age; chronic kidney disease; ACS; diabetes mellitus; multiple lesions; and long, overlapping, or bifurcation lesions. 18 Prevalence of late stent thrombosis may be higher in patients with MI compared with those with stable angina because of delayed vessel healing, greater strut penetration in MI with necrotic core, and greater thrombus burden. 19 Patients who discontinue thienopyridine therapy within 30 days are more likely to die within the following 11 months or be rehospitalized, but adequate data are not available regarding the benefits and risks of continuation of dual antiplatelet therapy beyond 12 months. 20 Consideration of tolerability of dual antiplatelet therapy is important in making decisions for prolonged antiplatelet therapy. The CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) trial examined the bleeding events over time. The instantaneous hazard for severe or moderate bleeding was initially higher for the clopidogrel plus aspirin group compared with the aspirin plus placebo group. 21 However, after approximately a 1-year period, there was no difference between the 2 groups, signifying that if the patients can tolerate dual antiplatelet therapy for 1 year, they are more likely to be able to safely continue prolonged therapy. Summary Intracoronary stenting has replaced balloon angioplasty as the PCI procedure of choice because of lower risk of restenosis. In summary, more recent data suggest that the benefits outweigh the risks of DESs compared with BMSs, and that the rate of DES placement will continue to rise. Pharmacists should be aware of the indications for dual antiplatelet therapy and the appropriate duration of dual antiplatelet therapy in patients undergoing PCI. Patients receiving a DES must be carefully selected to ensure long-term adherence to dual antiplatelet therapy in order to minimize the risk of late stent thrombosis. For patients undergoing PCI intracoronary stenting, dual antiplatelet therapy should be continued for at least 1 month in patients receiving a BMS during elective PCI, for 1 year in patients receiving a DES during elective PCI, for 1 year in patients with non ST-segment elevation ACS or STEMI receiving either a BMS or a DES, and possibly longer if the therapy is well tolerated. Author Affiliations: From the Department of Pharmacy Practice/Pharmacy Administration, Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, and the Cardiovascular Division, Department of Medicine, University of Pennsylvania, Philadelphia, PA. Funding Source: Financial support for this work was provided by Daiichi Sankyo, Inc and Eli Lilly and Company. Author Disclosure: Speakers bureau for Bristol-Myers Squibb and sanofi-aventis, and consultant for sanofi-aventis. Authorship Information: Concept and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript; and critical revision of the manuscript for important intellectual content. S46 n n March 2009
6 Assessing Coronary Vascular Risk Associated With Bare-Metal and Drug-Eluting Stents Address correspondence to: Sarah A. Spinler, PharmD, FCCP, BCPS (AQ Cardiology), Professor of Clinical Pharmacy, University of the Sciences in Philadelphia, Philadelphia College of Pharmacy, Department of Pharmacy Practice/Pharmacy Administration, 600 S 43rd St, Box GRI 108-T, Philadelphia, PA s.spinle@usip.edu. References 1. Smith SC, Feldman TE, Hirshfeld JW Jr, et al. ACC/ AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-Summary Article: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/ AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol. 2006;47(1): Grech ED. ABC of interventional cardiology: percutaneous coronary intervention. I: history and development. BMJ. 2003;326(7398): Dobesh PP, Stacy ZA, Ansara AJ, Enders JM. Drugeluting stents: a mechanical and pharmacologic approach to coronary artery disease. Pharmacotherapy. 2004;24(11): Shuchman M. Debating the risks of drug-eluting stents. N Engl J Med. 2007;356(4): van Werkum JW, dekorte FI, Heestermans AA, et al. High recurrence rates after a first episode of stent thrombosis: results from the Dutch Stent Thrombosis Study. American College of Cardiology Scientific Sessions/i2 Summit-SCAI Annual Meeting; March 29, 2008; Chicago, IL. 6. Curfman GD, Morrissey S, Jarcho JA, Drazen JM. Drugeluting coronary stents promise and uncertainty. N Engl J Med. 2007;356(10): Grines CL. Off-label use of drug-eluting stents: putting it in perspective. J Am Coll Cardiol. 2008;51(6): Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356(10): Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356(10): Mauri L, Silbaugh TS, Garg P, et al. Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med. 2008;359(13): Malenka DJ, Kaplan AV, Lucas FL, Sharp SM, Skinner JS. Outcomes following coronary stenting in the era of bare-metal vs the era of drug-eluting stents. JAMA. 2008;299(24): Applegate RJ, Sacrinty MT, Kutcher MA, et al. Offlabel stent therapy: 2-year comparison of drugeluting versus bare-metal stents. J Am Coll Cardiol. 2008;51(6): Marroquin OC, Selzer F, Mulukutla SR, et al. A comparison of bare-metal and drug-eluting stents for offlabel indications. N Engl J Med. 2008;358(4): Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369(9562): King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, et al Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation. 2008;117(2): Anderson JL, Adams CD, Antman EM, et al. ACC/ AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50(7):e1-e Antman EM, Hand M, Armstrong PW, et al Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/ AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation. 2008;117(2): Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation. 2007;115(6): Nakazawa G, Finn AV, Joner M, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation. 2008;118(11): Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation. 2006;113(24): Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49(19): VOL. 15, No. 2 n The American Journal of Managed Care n S47
Disclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More informationOral Antiplatelet Therapy in PCI/ACS. Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine
Oral Antiplatelet Therapy in PCI/ACS Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine Basic Concepts Thrombus Formation Two key elements:
More informationOptimal Duration and Dose of Antiplatelet Therapy after PCI
Optimal Duration and Dose of Antiplatelet Therapy after PCI Donghoon Choi, MD, PhD Severance Cardiovascular Center Yonsei University College of Medicine Optimal Duration of Antiplatelet Therapy after PCI
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationSupplementary Online Content
Supplementary Online Content Amin AP, Spertus JA, Cohen DJ, Chhatriwalla A, Kennedy KF, Vilain K, Salisbury AC, Venkitachalam L, Lai SM, Mauri L, Normand S-LT, Rumsfeld JS, Messenger JC, Yeh RW. Use of
More information1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES
1 Comparison of Ischemic and Bleeding Events After Drug- Eluting Stents or Bare Metal Stents in Subjects Receiving Dual Antiplatelet Therapy: Results from the Randomized Dual Antiplatelet Therapy (DAPT)
More informationCardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008.
Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008. ST Elevation Myocardial Infarction (STEMI)-Acute Coronary Syndrome Guidelines:
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationAnti-platelet therapies and dual inhibition in practice
Anti-platelet therapies and dual inhibition in practice Therapeutics; Sept. 25 th 2007 Craig Williams, Pharm.D. Associate Professor of Pharmacy Objectives 1. Understand the pharmacology of thienopyridine
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationAcute coronary syndromes (ACS), including unstable
n report n Acute Coronary Syndromes: Morbidity, Mortality, and Pharmacoeconomic Burden Daniel M. Kolansky, MD Abstract Acute coronary syndromes (ACS), which include unstable angina and myocardial infarction
More informationTiming of Surgery After Percutaneous Coronary Intervention
Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationPrasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center
Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationGRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY. Nick Collins February 2017
GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY Nick Collins February 2017 DISCLOSURES Before I commence Acknowledge.. Interventional Cardiologist Perception evolved. Interventional
More information2010, Metzler Helfried
Perioperative Strategies in Patients on Dual Antiplatelet Drug Therapy: Noncardiac Surgery H. Metzler Department of Anaesthesiology and Intensive Care Medicine Medical University of Graz, Austria What
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationPathology of percutaneous interventions (PCI) in coronary arteries. Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL
Pathology of percutaneous interventions (PCI) in coronary arteries Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL Percutaneous Coronary Intervention (PCI) Definition: transcatheter opening of
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationLessons learned From The National PCI Registry
Lessons learned From The National PCI Registry w a v e On Behalf of The Publication Committee of the National PCI Registry Objectives & Anticipated Achievements To determine the epidemiology of patients
More informationClinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center
Aging Research Volume 2013, Article ID 471026, 4 pages http://dx.doi.org/10.1155/2013/471026 Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at
More informationPrevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
More informationOUTCOMES WITH LONGTERM DUAL ANTIPLATELET THERAPY AFTER CORONARY ANGIOPLASTY Ashok Kumar Arigonda, K. Nagendra Prasad, O. Hareesh, R.
INDIAN JOURNAL OF CARDIOVACULAR DIEAE JOURNAL in women (IJCD) 016 VOL 1 IUE 3 ORIGINAL ARTICLE 1 OUTCOME WITH LONGTERM DUAL ANTIPLATELET THERAPY AFTER CORONARY ANGIOPLATY Ashok Kumar Arigonda, K. Nagendra
More informationOsler Journal Club Outcomes Research
Osler Journal Club Outcomes Research Malenka DJ, et al. Outcomes Following Coronary Stenting in the Era of Bare-Metal vs. the Era of Drug- Eluting Stents. JAMA 2008; 299(24):2868-2876 Mentor: Dr. Boulware
More informationDES in primary PCI for STEMI: contra
DES in primary PCI for STEMI: contra Philippe Gabriel Steg Department of Cardiology Hôpital Bichat Claude Bernard, AP-HP Université Paris VII Denis Diderot INSERM U-698 Paris, France Ph. Gabriel Steg -
More informationHow Long Patietns Will Be on Dual Antiplatelet Therapy?
How Long Patietns Will Be on Dual Antiplatelet Therapy? Ron Waksman,, MD, FACC Professor of Medicine (Cardiology) Georgetown University Associate Director, Division of Cardiology, Washington Hospital Center
More informationSurveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management
Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis Disclosures
More informationUnprotected Left Main Coronary Artery Disease in Patients With Low Predictive Risk of Mortality
Unprotected Left Main Coronary Artery Disease in Patients With Low Predictive Risk of Mortality Shun Watanabe, MD, Tatsuhiko Komiya, MD, Genichi Sakaguchi, MD, PhD, and Takeshi Shimamoto, MD, PhD Department
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationCLINICIAN INTERVIEW RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE. An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA
RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA Dr Lincoff is an interventional cardiologist and the Vice Chairman for Research
More informationVCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital
VCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital Complex PCI: Multivessel Disease George W. Vetrovec, MD. Kimmerling Chair of Cardiology VCU Pauley Heart Center Virginia
More informationA Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI
HORIZONS-AMI: A Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI Gregg W. Stone MD Columbia University Medical Center Cardiovascular Research Foundation Disclosures Gregg W. Stone
More informationHeart disease is the leading cause of death
ACS AND ANTIPLATELET MANAGEMENT: UPDATED GUIDELINES AND CURRENT TRIALS Christopher P. Cannon, MD,* ABSTRACT Acute coronary syndrome (ACS) is an important cause of morbidity and mortality in the US population
More informationBern-Rotterdam Cohort Study
Bern-Rotterdam Cohort Study Newer generation everolimus-eluting stents eliminate the risk of very late stent thrombosis compared with early generation sirolimus-eluting and paclitaxel-eluting stents Lorenz
More informationANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC. Seoul, Korea: April The problem is exaggerated: Data from Real World Registries
ANGIOPLASY SUMMIT 007 TCT ASIA PACIFIC Seoul, Korea: 5-7 7 April 007 15 min Plenary Session: State-of of-the-art Lectures The problem is exaggerated: Data from Real World Registries Antonio Colombo Centro
More informationIndications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014
Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014 Indications for cardiac catheterization Before a decision to perform an invasive procedure such
More informationClopidogrel has been evaluated in clinical trials that included cardiovascular patients
REVIEW ARTICLE Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations Lessons From the CAPRIE and CURE Studies Jack Hirsh, CM, MD, FRCPC, FRACP, FRSC, DSc; Deepak L. Bhatt, MD,
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationNine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large coronary vessel lesions
Journal of Geriatric Cardiology (2017) 14: 35 41 2017 JGC All rights reserved; www.jgc301.com Research Article Open Access Nine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large
More information2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease Developed in Collaboration with American Association for Thoracic Surgery, American
More informationAntiplatelet Therapy After PCI: How Much and How Long?
Antiplatelet Therapy After PCI: How Much and How Long? Adnan Kastrati Deutsches Herzzentrum, Munich, GERMANY Antiplatelet Therapy after PCI: How much and how long? The simplest and extreme response: Give
More informationMaintenance of Long-Term Clinical Benefit With Sirolimus-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction
Journal of the American College of Cardiology Vol. 55, No. 8, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/10/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.09.046
More informationAcute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine
Acute Coronary Syndrome Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Topics Timing is everything So many drugs to choose from What s a MINOCA? 2 Acute
More informationThe Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI
The Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI Interventional Cardiologist Cardiovascular Institute of the South Director of Cardiovascular Services St. Charles Parish
More informationTCT mdbuyline.com Clinical Trial Results Summary
TCT 2012 Clinical Trial Results Summary FAME2 Trial: FFR (fractional flow reserve) guided PCI in all target lesions Patients with significant ischemia, randomized 1:1 Control arm: not hemodynamically significant
More informationDrug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
More informationCoronary drug-eluting stents (DES) were first approved
Thrombosis in Coronary Drug-Eluting Stents Report From the Meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health,
More informationAntiplatelet therapy in myocardial infarction and coronary stent thrombosis Heestermans, Antonius Adrianus Cornelius Maria
University of Groningen Antiplatelet therapy in myocardial infarction and coronary stent thrombosis Heestermans, Antonius Adrianus Cornelius Maria IMPORTANT NOTE: You are advised to consult the publisher's
More informationClinical Investigations
Clinical Investigations Clinical Outcomes for Single Stent and Multiple Stents in Contemporary Practice Qiao Shu Bin, MD; Liu Sheng Wen, MD; Xu Bo, BS; Chen Jue, MD; Liu Hai Bo, MD; Yang Yue Jin, MD; Chen
More informationAcute coronary syndrome (ACS) is an
OVERVIEW OF MEDICAL MANAGEMENT OF ACUTE CORONARY SYNDROMES Robert B. Parker, PharmD * Acute coronary syndrome (ACS) is an umbrella term used to describe any group of symptoms of acute myocardial ischemia
More informationAcute Coronary syndrome
Acute Coronary syndrome 7th Annual Pharmacotherapy Conference ACS Pathophysiology rupture or erosion of a vulnerable, lipidladen, atherosclerotic coronary plaque, resulting in exposure of circulating blood
More informationUpdate on STEMI Guidelines. Manesh R. Patel, MD Assistant Professor of Medicine Duke University Medical Center
Update on STEMI Guidelines Manesh R. Patel, MD Assistant Professor of Medicine Duke University Medical Center All Rights Reserved, Duke Medicine 2008 Disclosures Research Grants: NHLB, AHRQ, AstraZeneca,
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Optimising Crossover from Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome [CAPITAL OPTI-CROSS] Monique Conway, PharmD, BCPS PGY-2 Cardiology Pharmacy
More information8/28/2018. Pre-op Evaluation for non cardiac surgery. A quick review from 2007!! Disclosures. John Steuter, MD. None
Pre-op Evaluation for non cardiac surgery John Steuter, MD Disclosures None A quick review from 2007!! Fliesheret al, ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and are for Noncardiac
More informationEarly and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
Journal of the American College of Cardiology Vol. 51, No. 21, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.04.002
More informationMINERVA MEDICA COPYRIGHT. Aspirin is accepted as standard antiplatelet. Dual antiplatelet therapy for primary and secondary prevention
This document is protected by international copyright laws. No additional reproduction is authorized. It is permitted for personal use to download and save only one file and print only one copy of this
More informationSTEMI 2014 YAHYA KIWAN. Consultant Cardiologist Head Of Cardiology Belhoul Specialty Hospital
STEMI 2014 YAHYA KIWAN Consultant Cardiologist Head Of Cardiology Belhoul Specialty Hospital Aspiration Thrombectomy Manual aspiration thrombectomy is reasonable for patients undergoing primary PCI. I
More informationWhat is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?
What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation? Keun-Ho Park, Myung Ho Jeong, Min Goo Lee, Jum Suk Ko,
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationHow to approach non-infarct related artery disease in patients with STEMI in a limited resource setting
How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting Ahmed A A Suliman, MBBS, FACP, FESC Associate Professor, University of Khartoum Interventional Cardiologist,
More informationClinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST How to manage antiplatelet treatment in patients with diabetes in acute coronary syndrome Lars Wallentin Professor of Cardiology, Chief Researcher Cardiovascular Science
More informationCase Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA
Case Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA Case History A 50-year-old man with type 1 diabetes mellitus and hypertension presents after experiencing 1 hour of midsternal chest pain that began after
More informationPercutaneous Coronary Interventions Without On-site Cardiac Surgery
Percutaneous Coronary Interventions Without On-site Cardiac Surgery Hassan Al Zammar, MD,FESC Consultant & Interventional Cardiologist Head of Cardiology Department European Gaza Hospital Palestine European
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationOtamixaban for non-st-segment elevation acute coronary syndrome
Otamixaban for non-st-segment elevation acute coronary syndrome September 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationThe Effect of Cilostazol on Stent Thrombosis After Drug-Eluting Stent Implantation
ORIGINAL ARTICLE DOI 10.4070 / kcj.2010.40.1.10 Print ISSN 1738-5520 / On-line ISSN 1738-5555 Copyright c 2010 The Korean Society of Cardiology Open Access The Effect of Cilostazol on Stent Thrombosis
More informationSheffield guidelines for the use of antiplatelets in the prevention and treatment of cardiovascular disease (October 2017)
Sheffield guidelines f the use of antiplatelets in the prevention and treatment of cardiovascular disease (October 2017) Approved by Sheffield Area Prescribing Committee and Sheffield Teaching Hospitals
More informationSupplementary Online Content
Supplementary Online Content Valle JA, Tamez H, Abbott JD, et al. Contemporary use and trends in unprotected left main coronary artery percutaneous coronary intervention in the United States: an analysis
More informationUpdate interventional Cardiology Hans Rickli St.Gallen
Update interventional Cardiology 2012 Hans Rickli St.Gallen 26.11.2012 Review of Literature ESC-Highlights TCT/AHA-Highlights Update interventional cardiology 2012 Structural Heart Disease Transcatheter
More informationAdults With Diagnosed Diabetes
Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et
More informationA Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction 1
More information- May Help Increase Appropriate Early Use in Acute Coronary Syndrome Patients -
MEDIA INVESTORS Ken Dominski John Elicker Bristol-Myers Squibb Bristol-Myers Squibb 609-252-5251 212-546-3775 ken.dominski@bms.com john.elicker@bms.com Amy Ba Felix Lauscher sanofi-aventis sanofi-aventis
More informationConflict of interest :None. Meta-analysis. Zhangwei Chen, MD
Meta-analysis Addition of Cilostazol to Conventional Dual Antiplatelet Therapy Reduces the Risk of Cardiac Events and Restenosis after Drug-Eluting Stent Implantation Zhangwei Chen, MD Department of Cardiology,
More informationGuideline for STEMI. Reperfusion at a PCI-Capable Hospital
MANSOURA. 2015 Guideline for STEMI Reperfusion at a PCI-Capable Hospital Mahmoud Yossof MANSOURA 2015 Reperfusion Therapy for Patients with STEMI *Patients with cardiogenic shock or severe heart failure
More informationGuidelines PATHOLOGY: FATAL PERIOPERATIVE MI NON-PMI N = 25 PMI N = 42. Prominent Dutch Cardiovascular Researcher Fired for Scientific Misconduct
PATHOLOGY: FATAL PERIOPERATIVE MI NON-PMI N = 25 PMI N = 42 Preoperative, Intraoperative, and Postoperative Factors Associated with Perioperative Cardiac Complications in Patients Undergoing Major Noncardiac
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationAntiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology
Antiplatelet and Anti-Thrombotic Therapy Ivan Anderson, MD RIHVH Cardiology Outline Anti-thrombotic therapy Risk stratification of stroke with atrial fibrillation DVT and PE treatment Pharmacology Anti-platelet
More informationThe Window for Fibrinolysis. Frans Van de Werf, MD, PhD Leuven, Belgium
The Window for Fibrinolysis Frans Van de Werf, MD, PhD Leuven, Belgium ESC STEMI Guidelines : December 2008 Reperfusion Therapy: Fibrinolytic Therapy Recommendations Class LOE In the absence of contraindications
More informationDESs in Multivessel Disease
DESs in Multivessel Disease Lessons learned from large registry experience. BY DANIEL W. CARLSON, MD, AND MARK A. TURCO, MD, FACC, FSCAI For patients with limitation of ordinary physical activity secondary
More informationAbstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department
ST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department decision-making. They have become the cornerstone of many ED protocols for
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationUPDATES FROM THE 2018 ANTIPLATELET GUIDELINES
UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES Claudia Bucci BScPhm, PharmD Clinical Coordinator, Cardiovascular Diseases Sunnybrook Health Sciences Centre 21st Annual Contemporary Therapeutic Issues in
More informationCardiac evaluation for the noncardiac. Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology
Cardiac evaluation for the noncardiac patient Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology Objectives! Review ACC / AHA guidelines as updated for 2009! Discuss new recommendations
More informationClopidogrel and ASA after CABG for NSTEMI
Clopidogrel and ASA after CABG for NSTEMI May 17, 2007 Justin Lee Pharmacy Resident University Health Network Objectives At the end of this session, you should be able to: Explain the rationale for antiplatelet
More informationOptimal antiplatelet and anticoagulant therapy for patients treated in STEMI network
Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs
More informationDrug-eluting stents and glycoprotein IIbIIIa inhibitors in the pharmacoinvasive management of ST elevation MI
Priority paper evaluation Drug-eluting stents and glycoprotein IIbIIIa inhibitors in the pharmacoinvasive management of ST elevation MI Evaluation of: Sanchez, P, Gimeno F, Ancillo P et al.: Role of the
More informationThe MAIN-COMPARE Registry
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationIs there enough evidence for DAPT after endovascular intervention for PAOD?
Is there enough evidence for DAPT after endovascular intervention for PAOD? Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern Disclosure Speaker name:...i. Baumgartner...
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationReview Article Comparison of 12-Month Outcomes with Zotarolimus- and Paclitaxel-Eluting Stents: A Meta-Analysis
International Scholarly Research Network ISRN Cardiology Volume 2011, Article ID 675638, 6 pages doi:10.5402/2011/675638 Review Article Comparison of 12-Month Outcomes with Zotarolimus- and Paclitaxel-Eluting
More information